Sei Investments Co. Sells 138,197 Shares of Grifols, S.A. $GRFS

Sei Investments Co. trimmed its holdings in Grifols, S.A. (NASDAQ:GRFS) by 9.9% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,251,579 shares of the biotechnology company’s stock after selling 138,197 shares during the period. Sei Investments Co.’s holdings in Grifols were worth $10,038,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of GRFS. Mirae Asset Global Investments Co. Ltd. lifted its stake in Grifols by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 1,212 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Grifols by 50.3% in the first quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 2,998 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 4,604 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 1,096 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in Grifols during the second quarter valued at approximately $95,000.

Grifols Price Performance

NASDAQ GRFS opened at $7.87 on Friday. The company has a 50-day moving average price of $7.51 and a 200-day moving average price of $8.17. Grifols, S.A. has a 52 week low of $6.96 and a 52 week high of $10.88. The company has a quick ratio of 0.85, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $5.36 billion, a P/E ratio of 41.42, a PEG ratio of 0.29 and a beta of 0.67.

Grifols Dividend Announcement

The firm also recently announced a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were given a dividend of $0.0945 per share. The ex-dividend date was Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Analyst Ratings Changes

GRFS has been the topic of several research reports. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings lowered shares of Grifols from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.